Navigation Links
DURECT to Present at the UBS Global Specialty Pharmaceuticals Conference
Date:5/12/2011

CUPERTINO, Calif., May 12, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the UBS Global Specialty Pharmaceuticals Conference on Tuesday, May 24 at 10:00 a.m. London Time.  The conference is being held at the UBS offices in London, England  

(Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at  www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... YORK , May 20, 2013  Echo Pharma ... 2.5 of the Irish Takeover Rules (the "Announcement"), a ... plc (NYSE: ELN ) to $12.50 per ... cash confirmed and not conditional on due diligence.  The ... Royalty Pharma has reserved the right to waive down ...
(Date:5/20/2013)... , May 20, 2013  Atlantic Pharmaceuticals, Inc., ... is commercializing a unique technology to deter prescription ... President, Anthony Soscia , has ... Atlanta Business Chronicle ,s Health-Care Heroes Awards. The ... Business Chronicle to honor individuals and organizations demonstrating ...
(Date:5/20/2013)... May 20, 2013  Rhythm announced today the presentation ... higher prevalence of gastroparesis symptoms among diabetic patients in ... is high among patients with both type 1 and ... among those with the more common type 2 disease. ... MD, PhD, Associate Professor of Medicine at Harvard Medical ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
(Date:5/20/2013)... NL, 20 May 2013 While Huntington,s disease ... anticipates that new disease-modifying therapies in development may ... of HD research depends upon the identification of ... evaluate therapies, and these biomarkers may eventually be ... could be especially helpful to monitor changes during ...
(Date:5/20/2013)... Horizon NJ Health, New Jersey’s largest ... it has earned a Commendable Accreditation status from ... Health is a wholly owned subsidiary of Horizon Blue ... Health Plan Accreditation is a nationally recognized program that ... plans provide to their members. Health Plan Accreditation performance ...
(Date:5/20/2013)... May 20, 2013 The American Society ... for Bright Pink®, the organization that empowers young women to ... end of 2012. Thanks to its members, ASCP raised more ... is involved in Relay for Life at the local level. ... he decided to donate. “I was made aware of the ...
(Date:5/20/2013)... The nationwide law firm of Bernstein Liebhard LLP ... imaging (MRI) can be used to predict metal-on-metal hip ... experiencing symptoms. According to an article published on May ... MRI detected synovitis (tissue damage) in 68% of asymptomatic patients ... causes, the detection rate was 75%, while MRIs were able ...
(Date:5/20/2013)... MONDAY, May 20 (HealthDay News) -- Boys who are ... likely to become obese adults as those who didn,t ... 30-year study shows. Researchers found that men with ... (BMI) and obesity, even if they no longer had ... well-off or poor, they tended toward obesity. "The ...
Breaking Medicine News(10 mins):Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 2Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 2Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 4Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3
... Researchers may have found a more potent risk factor for melanoma ... disease. In a new study, scientists at NYU Langone Medical Center ... of melanoma in women under the age of 50. The ... Clinical Cancer Research and will be published in the ...
... N.C. Numerous studies have shown a relationship between ... with breast cancer. In a study published today in ... , an investigation of coping strategies and quality of ... QOL determines the use of coping strategies. , "It ...
... March 24 The American Cancer Society Cancer Action ... and the Campaign for Tobacco-Free Kids applaud Senator Frank ... Drug Administration to exert its authority and immediately remove ... quoted numerous times in many publications during the past ...
... emphasizes values-based curriculum PHOENIX, March 24 In answer ... the need for more values-driven leaders, Grand Canyon ... it rewards to high academic achievers as well as ... is our own higher education stimulus package," said GCU ...
... educate Americans about their risk of type 2 diabetesPORT ST. ... Day. The American Diabetes Association urges all Americans to ... it. To help educate the public, the American Diabetes ... Supply, Inc., have teamed up to provide an online video ...
... behavioral traits, susceptibility to certain diseases , , TUESDAY, ... 1,362 copy number variations (CNVs) in the human genome ... -- differences in gene copy numbers caused by deletions, ... a large amount of human diversity and can also ...
Cached Medicine News:Health News:NYU study finds new risk factor for melanoma in younger women 2Health News:NYU study finds new risk factor for melanoma in younger women 3Health News:Quality of life may impact coping strategies of young women with breast cancer 2Health News:Quality of life may impact coping strategies of young women with breast cancer 3Health News:Statement of the American Cancer Society Cancer Action Network, American Heart Association, American Lung Association and the Campaign for Tobacco-Free Kids 2Health News:Grand Canyon University Increases Academic Scholarships 2Health News:Grand Canyon University Increases Academic Scholarships 3Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 2Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 3Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 4Health News:Study IDs Variations in Black, White Genomes 2
Reciprocating shaker specifically for platelet bags....
... by the adrenal cortex, the corpus luteum, ... other steroids, progesterone is synthesized from cholesterol ... Progesterone produced by the adrenal cortex and ... steroidogenic pathways, with only a small amount ...
No cross-reaction with human pro-insulin and C-peptide....
ELISA for the detection of Insulin....
Medicine Products: